Loading clinical trials...
Loading clinical trials...
A Phase IV, Open-Label, Single-Sequence Pilot Study to Characterize the Pharmacokinetics of a 400mg Oral Dose of Raltegravir in the Cervicovaginal Fluids of HIV-Infected Women
Conditions
Interventions
Raltegravir (Isentress®)
Locations
1
United States
The University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, United States
Start Date
August 1, 2008
Primary Completion Date
September 1, 2009
Completion Date
September 1, 2009
Last Updated
October 25, 2011
NCT07071623
NCT04929028
NCT01875588
NCT03087253
NCT07199335
NCT05419024
Lead Sponsor
Kristine Patterson, MD
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions